Navigation Links
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Date:12/30/2011

AMSTERDAM, December 30, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

Under the terms of the transaction, AMT has agreed to issue 7,352,938 new shares at a price of € 0.34 per share, being the closing price on December 29, 2011, when the shares were placed. The proceeds of this issue will provide additional flexibility to further explore its strategic options to secure the financial stability of the Company. The proceeds do not eliminate the Company's negative equity position, which will continue after completion of the equity raising, which is expected to take place on or around January 4, 2012, and the Company's financial prospects remain as described in the announcement of December 15, 2011.

As a result of the private placement, the Company's issued share capital will amount to 31,051,454 shares.

Pursuant to the Financial Supervision Act (Wet op het financieel toezicht) there is no obligation to publish a prospectus approved by the Netherlands Authority for the Financial Markets (Autoriteit Financiele Markten) in relation to the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam. The Netherlands Authority for the Financial Markets does not supervise the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the del
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
5. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
7. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... N.J. , Aug. 27, 2014  A ... potential to help physicians better identify early-stage disease, ... and disability, according to a new study in ... Quest Diagnostics (NYSE: DGX ) and ... the 14-3-3eta protein outperformed conventional antibody-serum testing, including ...
(Date:8/27/2014)... -- Research and Markets has announced the ... Paper Industry Report 2014" report to their offering. ... Paper Industry Report 2014 is a professional and in-depth ... for pulp & paper industry. The report ... classifications, applications and industry chain structure. The enzyme for ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Ala., Jan. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and Dr. William P. Sheridan, Chief Medical ... J.P. Morgan 27th Annual Healthcare Conference on Thursday, January 15, ... be held January 12-15, 2009 in San Francisco.A link to ...
... DNDN ) today announced that management will present ... Francisco on Thursday, January 15, 2009 at 11:00 a.m. PT. ... be accessible through the Investor Relations section of the Dendreon ... to the live webcast, it will be archived on the ...
... Medical, Inc., the global leader in devices for clot ... has completed a $15 million round of financing. ... New Enterprise Associates, Inc. (NEA) and includes other existing ... the last several months made the opportunity to participate ...
Cached Biology Technology:BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3Concentric Medical Closes on $15 Million Financing 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... growing number of studies have shown that ... pathogenesis of Parkinson,s disease. Previous studies from ... University in China have shown that baicalin ... reduced divalent metal transporter 1 expression, and ... nigra of rotenone-induced Parkinson,s disease rats. However, ...
(Date:8/27/2014)... the Happy Camp Complex of fires had consumed 24,939 ... had consumed 35,530 as of eight hours ago. ... Camp Ranger District of the Klamath National Forest when ... 2014. All but three of those fires are now ... contained fires and their size at containment: Delta, 150 ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... 2010) The New York Stem Cell Foundation (NYSCF) today ... postdoctoral scientists join 15 accomplished stem cell researchers from leading ... NYSCF has awarded 23 fellowships to date. ... most competitive postdoctoral fellowship programs in the world, has so ...
... year The International Institute for Species Exploration at Arizona State ... previous calendar year. The list for 2009 was published to ... birth of Carl Linnaeus. It contains only two new plant ... Botanical Journal of the Linnean Society . ...
... SPRING HARBOR, N.Y. (Tues., June 1, 2010) -- ... frequently used techniques in RNA analysis. Electrophoresis is ... quality assessment. Gels are involved in a wide ... and analyzing processing reactions. The two most common ...
Cached Biology News:NYSCF awards fellowships to 8 innovative stem cell scientists 2NYSCF awards fellowships to 8 innovative stem cell scientists 3Rare carnivorous plant on top 10 list of newly discovered species 2Electrophoresis of RNA, avian imaging featured in June's Cold Spring Harbor Protocols 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
UV-NIR light source for USB2000, HR4000, HR2000+...
Biology Products: